Literature DB >> 2174053

Correlation between expression of 5-lipoxygenase-activating protein, 5-lipoxygenase, and cellular leukotriene synthesis.

G K Reid1, S Kargman, P J Vickers, J A Mancini, C Léveillé, D Ethier, D K Miller, J W Gillard, R A Dixon, J F Evans.   

Abstract

Previous studies involving transfection of cDNAs for 5-lipoxygenase-activating protein (FLAP) and 5-lipoxygenase into osteosarcoma cells have shown that both these proteins are essential for leukotriene synthesis (Dixon, R. A. F., Diehl, R. E., Opas, E., Rands, E., Vickers, P. J., Evans, J. F., Gillard, J. W., and Miller, D. K. (1990) Nature 343, 282-284). In the present study we show that FLAP is present in a variety of cells known to produce leukotrienes, but is absent from a number of cells which do not synthesize leukotrienes. Furthermore, differentiation of the human promyelocytic HL-60 cell line towards granulocytic cells following exposure to dimethylsulfoxide is associated with the concurrent induction of both FLAP and 5-lipoxygenase and an increased capacity to synthesize leukotrienes. Cellular leukotriene synthesis in this system is functionally dependent on FLAP as shown by its inhibition by the leukotriene biosynthesis inhibitor MK-886, a compound which specifically binds to FLAP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174053

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Joint tissues amplify inflammation and alter their invasive behavior via leukotriene B4 in experimental inflammatory arthritis.

Authors:  Mei Chen; Bing K Lam; Andrew D Luster; Simona Zarini; Robert C Murphy; Angela M Bair; Roy J Soberman; David M Lee
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

2.  Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells.

Authors:  E A Mellor; A Maekawa; K F Austen; J A Boyce
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  Leukotriene C4 Potentiates IL-33-Induced Group 2 Innate Lymphoid Cell Activation and Lung Inflammation.

Authors:  Sean J Lund; Alex Portillo; Kellen Cavagnero; Rachel E Baum; Luay H Naji; Jana H Badrani; Amit Mehta; Michael Croft; David H Broide; Taylor A Doherty
Journal:  J Immunol       Date:  2017-06-30       Impact factor: 5.422

4.  Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes.

Authors:  Tanya M Laidlaw; Molly S Kidder; Neil Bhattacharyya; Wei Xing; Shiliang Shen; Ginger L Milne; Mariana C Castells; Heng Chhay; Joshua A Boyce
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

Review 5.  Prostaglandin E2 as a Regulator of Immunity to Pathogens.

Authors:  Giovanny J Martínez-Colón; Bethany B Moore
Journal:  Pharmacol Ther       Date:  2017-12-22       Impact factor: 12.310

6.  Ligation of CD40 receptor in human B lymphocytes triggers the 5-lipoxygenase pathway to produce reactive oxygen species and activate p38 MAPK.

Authors:  Yun Jung Ha; Hee Jung Seul; Jong Ran Lee
Journal:  Exp Mol Med       Date:  2011-02-28       Impact factor: 8.718

7.  Transforming growth factor beta upregulates 5-lipoxygenase activity during myeloid cell maturation.

Authors:  D Steinhilber; O Rådmark; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

8.  Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family.

Authors:  R J Boado; W M Pardridge; H V Vinters; K L Black
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 9.  Leukotriene B4 and platelet-activating factor in human skin.

Authors:  L Michel; L Dubertret
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

10.  Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4.

Authors:  B K Lam; K Xu; M B Atkins; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.